Attacks affecting hospitals, healthcare workers and patients in conflict zones have risen sharply during 2026, with the World Health Organization recording an average of more than four attacks every day.

The incidents have been documented across conflicts including Ukraine and Gaza, where health systems already face severe pressure from casualties, damaged infrastructure, displacement and shortages of medicines and equipment.

Violence against healthcare creates consequences that extend far beyond the immediate site of an attack.

When a hospital is damaged, communities may lose emergency surgery, maternity care, dialysis, cancer treatment and routine medical services simultaneously.

The effect can persist for months even when an individual strike causes relatively few immediate casualties.

Healthcare workers face another layer of risk.

Doctors, nurses, paramedics and ambulance crews often remain in conflict zones precisely when infrastructure is deteriorating and patient numbers are increasing.

If workers are killed, injured or forced to leave, replacing their specialised skills can be extremely difficult.

International humanitarian law provides protections for medical personnel, facilities and transport during armed conflict.

Those protections, however, depend on combatants respecting the distinction between military objectives and civilian healthcare.

WHO has repeatedly warned that attacks on medical infrastructure undermine both immediate humanitarian response and the long-term viability of national health systems.

The scale reported in 2026 suggests healthcare protection is becoming a central public-health issue in modern warfare.

This is particularly serious because conflicts increasingly occur in densely populated urban areas where hospitals may be serving very large civilian populations.

A functioning hospital is not merely another building in a conflict zone.

It is part of the infrastructure that determines whether civilians survive injury, childbirth, infection and chronic illness during war.

The rise to more than four attacks per day shows that protecting healthcare can no longer be treated as a secondary humanitarian concern.

It is a fundamental requirement for limiting the human consequences of armed conflict.

Four major international organisations have agreed to extend their One Health Joint Plan of Action through 2029, reinforcing global cooperation against health threats that cross the boundaries between humans, animals and the environment.

The partnership brings together the World Health Organization, Food and Agriculture Organization, United Nations Environment Programme and World Organisation for Animal Health.

The One Health concept begins with a simple reality: human health cannot always be separated from animal health or environmental conditions.

Many emerging infectious diseases originate in animals before crossing into humans. Antimicrobial resistance can develop through antibiotic use across human medicine, livestock and food production. Environmental degradation and climate change can also alter how disease-carrying animals and insects interact with human populations.

The extended plan is therefore intended to improve coordination between sectors that traditionally operate separately.

Rather than waiting for an outbreak to become a human-health emergency, One Health programmes aim to detect risks earlier across animal populations, agriculture and ecosystems.

The renewed plan will remain the shared framework for international cooperation on preventing, detecting and responding to threats at the human-animal-plant-ecosystem interface.

The approach has become increasingly important after repeated outbreaks of zoonotic diseases around the world.

Nipah virus, avian influenza, Ebola and coronaviruses all demonstrate that pathogens can move across species barriers, sometimes with severe consequences.

India has direct experience with this challenge.

WHO has documented Nipah infections in India during 2026, including confirmed cases in West Bengal earlier in the year and another confirmed case in Kerala in June.

One Health therefore has practical relevance to India as well as global public-health systems.

However, collaboration across health, veterinary, agricultural and environmental agencies can be difficult because each has separate budgets, institutions and priorities.

The value of the framework will ultimately depend on whether cooperation occurs operationally rather than only through international declarations.

The next major outbreak may not begin in a hospital. It could begin in an animal population, a farm, a forest or another changing ecosystem.

Extending the One Health plan to 2029 recognises that reality.

The strongest public-health systems of the future will not simply react faster after people become sick; they will attempt to identify emerging threats before widespread human transmission begins.

The World Health Organization has defended the scientific basis of childhood vaccination schedules after the United States ordered major changes to its recommended immunisation programme.

US President Donald Trump signed an executive order calling for the country’s recommended childhood schedule to be reduced to 11 immunisations and for the combined measles, mumps and rubella vaccine eventually to be replaced by separate injections.

WHO responded by emphasising that vaccine schedules are developed through decades of scientific research and are tailored according to disease risks, population needs and national health systems.

WHO spokesperson Tarik Jašarević said international recommendations draw on more than 60 years of vaccination research and assessment by independent expert groups.

The controversy is particularly significant around the MMR vaccine.

The US order calls for measles, mumps and rubella to be administered separately once individual vaccines become available.

At present, however, separate vaccines for the three diseases are not licensed or routinely manufactured in the United States.

Experts interviewed by Reuters said developing, approving and manufacturing separate vaccines could take years and potentially as long as a decade.

Merck and GSK, which manufacture combined MMR vaccines in the United States, have said there is no published scientific evidence showing a benefit from separating the injections. Decades of evidence support the safety of the combined vaccine.

Public-health specialists are also concerned that requiring additional appointments could create opportunities for children to miss one or more vaccinations.

Vaccination schedules are designed partly around when children are most vulnerable to particular diseases and when their immune systems are best positioned to respond.

Changing that schedule therefore requires more than simply reducing the number of injections.

Childhood vaccination policy is a legitimate subject for continuing scientific review, but changes should follow new evidence rather than political preference alone.

The current dispute illustrates why comparisons between countries can be misleading: different nations face different disease risks and healthcare conditions.

For parents, the essential distinction is between scientific uncertainty that genuinely requires further study and claims that have already been repeatedly tested and rejected by evidence.

The World Health Organization and the Lions Clubs International Foundation have launched a new three-year partnership aimed at expanding access to mental-health, neurological and substance-use services in Nepal and Jordan.

The initiative forms part of WHO’s Special Initiative for Mental Health and is scheduled to continue until the end of 2028.

WHO estimates that more than one billion people worldwide live with a mental-health condition, yet access to appropriate care remains extremely uneven.

In some countries, the treatment gap for people living with mental-health conditions can exceed 95%, meaning only a small fraction of those who need care receive it.

The new programme will use different approaches in the two countries.

In Jordan, the partnership plans to establish counselling services in East Amman and strengthen acute secondary mental-health care for children and adults at Al Basheer Hospital.

In Nepal, the project will create psychosocial-support mental-health corners in ten district hospitals and support the implementation of the country’s national framework for school mental health.

The school component is especially important.

Mental-health difficulties frequently begin during childhood or adolescence, yet services are often concentrated in large hospitals and accessed only after conditions become severe.

Providing support closer to schools and communities could allow problems to be identified earlier.

The partnership will also focus on awareness and reducing stigma, because expanding the number of treatment locations is not sufficient if people remain reluctant to seek help.

WHO’s broader approach increasingly emphasises community-based mental healthcare rather than relying only on psychiatric institutions.

That shift reflects the reality that mental health is linked to education, employment, family stability and physical health, making early support important far beyond the healthcare system itself.

The most important aspect of the programme is not the creation of new facilities alone.

It is the attempt to move mental-health care closer to the places where people live, study and seek ordinary medical treatment.

If Nepal and Jordan can demonstrate that community-based services improve early access and reduce stigma, the model could offer useful lessons for other countries facing severe shortages of mental-health professionals.

The US Food and Drug Administration has approved a new brain-imaging agent designed to help doctors assess patients for Alzheimer’s disease by making abnormal tau-protein deposits visible during PET scans.

The product, called Tauklarify, is developed by Lantheus Holdings and is injected into a patient before positron-emission tomography imaging. It is intended for adults with cognitive impairment who are being evaluated for Alzheimer’s disease.

Alzheimer’s is associated with abnormal changes in the brain involving proteins including beta-amyloid and tau.

Tau forms abnormal structures inside neurons as the disease progresses, and its distribution can provide physicians with additional information about underlying neurodegeneration.

The FDA approval was supported by two studies in which independent readers assessed PET scans from more than 500 participants.

However, the new scan should not be interpreted as a definitive stand-alone Alzheimer’s test.

According to the company, a positive Tauklarify scan does not by itself prove that a patient has clinically significant tau pathology, while a negative scan does not completely exclude it.

Doctors must therefore interpret the imaging alongside symptoms, cognitive assessment and other clinical information.

That distinction is particularly important because Alzheimer’s diagnosis is becoming more technologically sophisticated.

For years, definitive evidence of certain disease-related brain changes was difficult to obtain while a patient was alive. Modern imaging and biomarker tests are increasingly allowing physicians to identify biological signs of the disease earlier and with greater precision.

The value of tau imaging may also increase as pharmaceutical research develops treatments aimed directly at tau.

At present, many of the most prominent Alzheimer’s therapies target amyloid rather than tau, meaning tau imaging remains more specialised in routine clinical practice.

Tauklarify does not cure Alzheimer’s, nor does a PET scan by itself provide a complete diagnosis.

Its importance lies in giving clinicians another tool to see biological changes associated with the disease inside the living brain.

As Alzheimer’s treatment becomes increasingly dependent on identifying the correct biological pathway in the correct patient, better diagnostic precision could become almost as important as new medicines themselves.

India is considering a wide-ranging overhaul of its health-insurance system as policymakers look for ways to control rapidly rising healthcare costs and make private medical treatment more predictable for patients.

Among the measures under discussion are benchmarked treatment rates agreed between hospitals and insurers, a standard list of admissible treatments and wider use of the National Health Claims Exchange. Recommendations are expected from a panel chaired by the Insurance Regulatory and Development Authority of India, with implementation to follow after the proposals are finalised.

The reforms are being considered against a difficult cost backdrop.

Industry estimates cited by Reuters put medical inflation in India at roughly 12% to 14% annually, among the highest levels in Asia. Private hospital care is considerably more expensive than treatment in public facilities, increasing the financial burden on households that depend on private healthcare.

One of the central ideas is to reduce the large variation in the amounts hospitals charge insurers for similar procedures.

Benchmarking treatment prices could potentially reduce billing disputes and make insurance products easier for consumers to compare. A uniform list of admissible treatments could also make it clearer what is and is not covered under a policy.

Another proposed reform is wider adoption of the National Health Claims Exchange, a digital platform developed by the Health Ministry and insurance regulator to create a common format for hospitals and insurers to exchange claims information.

If implemented effectively, such a system could reduce the time spent verifying bills and allow patients to complete insurance-supported hospital discharge more quickly.

The government is also examining a standard health-insurance product that insurers could be required to offer alongside their existing policies.

However, standardisation is not automatically the same as affordability.

If treatment prices continue rising faster than household incomes, insurance premiums may also rise. Reform therefore needs to address both administrative complexity and the underlying cost of medical care.

India’s health-insurance problem is not simply that policies are difficult to understand. It is that medical treatment itself is becoming increasingly expensive.

Standard pricing, clearer coverage rules and faster claims settlement could improve the system significantly. But the strongest long-term outcome would be one in which patients receive greater price transparency before treatment and are protected from unexpectedly large medical bills.

The proposals are still under discussion, so they should be treated as planned reforms rather than rules already in force.